Clinical trials: in Romania
Focal Epilepsy
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
- Trial name
- RISE 3 (NCT06309966)
- Testing
- BHV-7000
- Where
- 150 sites in United States, Australia and 14 more
- Volunteers
- 390 people
- Sponsor
- Biohaven Therapeutics Ltd.
Chronic Hepatitis D Infection
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection
This study is designed to assess safety, pharmacokinetics, and efficacy ABI-6250 in participants with Chronic Hepatitis D Virus Infection.
- Trial name
- NCT07762027
- Testing
- ABI-6250
- Where
- 22 sites in France, Georgia and 9 more
- Volunteers
- 80 people
- Sponsor
- Assembly Biosciences
Crohn's Disease (CD)
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease
This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of Upadacitinib (ABT-494).
- Trial name
- NCT02782663
- Testing
- ABT-494
- Where
- 61 sites in United States, Belgium and 16 more
- Volunteers
- 107 people
- Sponsor
- AbbVie
Carcinoma, Non-Small-Cell Lung
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
The study will compare the efficacy and safety of entrectinib with crizotinib in participants with advanced or metastatic ROS1 non-small cell lung cancer (NSCLC).
- Trial name
- NCT04603807
- Testing
- Entrectinib, Crizotinib
- Where
- 61 sites in Brazil, China and 16 more
- Volunteers
- 217 people
- Sponsor
- Hoffmann-La Roche
Urothelial Carcinoma, Non-Small Cell Lung Cancer
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
This is a non-interventional, multi-country, multi-centre, multiple cohort prospective study, with retrospective collection of prior medical/treatment history data from medical records, designed to assess the real-world outcomes…
- Conditions
- Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma
- Trial name
- IMreal (NCT03782207)
- Testing
- Atezolizumab
- Where
- 257 sites in Argentina, Austria and 28 more
- Volunteers
- 2,756 people
- Sponsor
- Hoffmann-La Roche
Hyperkalaemia
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia
Sodium zirconium cyclosilicate has been shown to be effective and safe in adults for the treatment of hyperkalaemia, and therefore it is expected to be beneficial in children.
- Trial name
- PEDZ-K (NCT03813407)
- Testing
- Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level, Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1), Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2)
- Where
- 70 sites in United States, Brazil and 11 more
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
Acne Vulgaris
Efficacy and Tolerability Evaluation of a Novel Dermo-cosmetic Product for Mild-to-moderate Acne
The goal of this non-interventional, observational study is to evaluate the real-world efficacy and tolerance of a novel dermocosmetic cream containing 15% Azelaic acid and a complex of active ingredients (α-AZ cream) in patients…
- Trial name
- NCT07759505
- Where
- Romania
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- ISISPHARMA
Major Depressive Disorder
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
- Trial name
- NCT06911112
- Testing
- NBI-1065845
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 200 people
- Sponsor
- Neurocrine Biosciences
Hematopoietic Neoplasm
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
Primary Objective: To evaluate the efficacy of daily oral doses of 400 mg or 500 mg of SAR302503 (Investigational Medicinal Product, IMP) compared to placebo in the reduction of spleen volume as determined by magnetic resonance…
- Trial name
- JAKARTA (NCT01437787)
- Testing
- SAR302503
- Where
- 101 sites in United States, Australia and 23 more
- Volunteers
- 289 people
- Sponsor
- Bristol-Myers Squibb
Chronic Inflammatory Demyelinating Polyneuropathy
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
This is a multi-center, randomized, quadruple-blind, placebo-controlled study to evaluate the efficacy and safety of batoclimab in adult participants with active CIDP.
- Trial name
- NCT05581199
- Testing
- Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly
- Where
- 98 sites in United States, Argentina and 19 more
- Volunteers
- 94 people
- Sponsor
- Immunovant Sciences GmbH
Asthma
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.
- Trial name
- NCT06376045
- Testing
- Rocatinlimab
- Where
- 154 sites in United States, Argentina and 17 more
- Volunteers
- 317 people
- Sponsor
- Amgen
Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
- Trial name
- KRYSTAL-12 (NCT04685135)
- Testing
- MRTX849, Docetaxel
- Where
- 380 sites in United States, Australia and 22 more
- Volunteers
- 453 people
- Sponsor
- Mirati Therapeutics Inc.
Chronic Inflammatory Demyelinating Polyneuropathy
An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This is an open-label extension (OLE) study designed to evaluate the long-term safety and tolerability of batoclimab in participants with CIDP who have completed Study IMVT-1401-2401 (NCT05581199).
- Trial name
- NCT07188844
- Testing
- Batoclimab
- Where
- 30 sites in United States, Argentina and 9 more
- Volunteers
- 26 people
- Sponsor
- Immunovant Sciences GmbH
Crohn's Disease
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.
- Trial name
- VIVID-2 (NCT04232553)
- Testing
- Mirikizumab
- Where
- 322 sites in United States, Argentina and 30 more
- Volunteers
- 996 people
- Sponsor
- Eli Lilly and Company
Gastric Cancer, Gastroesophageal Junction Cancer
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC)…
- Trial name
- NCT06731478
- Testing
- Trastuzumab Deruxtecan, pembrolizumab, Trastuzumab
- Where
- 250 sites in United States, Argentina and 24 more
- Volunteers
- 726 people
- Sponsor
- Daiichi Sankyo
Periodontal Diseases, Malocclusion
Influence of Finishing Clear Aligner Marginal Termination Design on Subgingival Periodontal Microbiota During Orthodontic Treatment: A Split-Mouth Study.
The goal of this clinical trial is to learn whether the edge design of a finishing orthodontic clear aligner at the gumline affects the bacteria living in the groove between the tooth and the gum (the gingival sulcus) in patients…
- Conditions
- Periodontal Diseases, Malocclusion, Oral Health
- Trial name
- PATHO-ALIGN (NCT07533058)
- Testing
- CA Pro tri-layer finishing clear aligner (SCHEU-DENTAL GmbH)
- Where
- Romania
- Volunteers
- 36 people
- Sponsor
- George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu Mures
Breast Cancer, Early Breast Cancer
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease…
- Trial name
- CAMBRIA-2 (NCT05952557)
- Testing
- Camizestrant, Tamoxifen, Anastrozole
- Where
- 661 sites in United States, Argentina and 42 more
- Volunteers
- 5,511 people
- Sponsor
- AstraZeneca
Generalized Myasthenia Gravis, gMG
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
The primary purpose of this study is to measure the efficacy and safety of efgartigimod IV compared to placebo in participants with Acetylcholine Receptor Binding Antibody (AChR-Ab) seronegative Generalized Myasthenia Gravis…
- Conditions
- Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis
- Trial name
- ADAPT SERON (NCT06298552)
- Testing
- Efgartigimod IV
- Where
- 91 sites in United States, Belgium and 20 more
- Volunteers
- 119 people
- Sponsor
- argenx
Multiple Sclerosis
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
- Trial name
- NCT01892722
- Testing
- Interferon beta-1a, Fingolimod
- Where
- 73 sites in United States, Australia and 23 more
- Volunteers
- 240 people
- Sponsor
- Novartis Pharmaceuticals
Alopecia Areata
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
This is a parallel, Phase 2 multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study to investigate the efficacy and safety of subcutaneous (SC) injections of amlitelimab treatment as monotherapy in…
- Trial name
- NCT06444451
- Testing
- Amlitelimab
- Where
- 74 sites in United States, Argentina and 14 more
- Volunteers
- 166 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.